Cancer treatment world first in Leeds
A patient at Leeds Cancer Centre has become the first in the world to receive radiotherapy using new tools co-developed by the University of Leeds, Leeds Teaching Hospitals NHS Trust and RaySearch. After 10 years of research, the tools were introduced in the latest version of RaySearch’s RayStation treatment-planning system and help clinicians tailor reirradiation by accounting for patients’ anatomy and previous treatment. The patient received five treatment sessions, marking the tools’ first use in clinical practice.
A Leeds patient has become the first in the world to receive radiotherapy using advanced tools co-developed by the University of Leeds.
The tools, which allow patients to receive more radiotherapy in previously treated areas of the body, are the result of 10 years' research and development by the team: a partnership between the University, Leeds Teaching Hospitals NHS Trust and radiotherapy software company RaySearch. Now, the first patient in the world to be treated with the tools has received a course of five treatment sessions at Leeds Cancer Centre.
This milestone demonstrates what can be achieved when university researchers, NHS healthcare professionals and industry work together to address the challenges faced by cancer patients.
Professor Nick Plant, Pro-Vice-Chancellor: Research and Innovation
The research was led at the University of Leeds by a multidisciplinary team of clinicians and medical physicists through Cancer Research UK Radiation Research Centre of Excellence (RadNet Leeds). The work has also been supported by Yorkshire Cancer Research and the Medical Research Council.
Treatment challenges
Almost half of all people diagnosed with cancer in the UK receive radiotherapy as part of their treatment. Healthy tissues can tolerate only a limited amount of radiation over a lifetime, so if further radiotherapy – known as reirradiation - is needed, it can be challenging to find the right dose. Exposing healthy tissue again can increase the risk of long-term side effects, including pain, scarring, nerve damage, organ dysfunction and delayed healing.
Dr Louise Murray, Associate Professor in Clinical Oncology in the University’s School of Medicine, said: “Reirradiation can be an effective treatment option for patients who have already received radiotherapy. This can offer major benefits to patients, including delaying or avoiding chemotherapy or surgery.
“Up until now it has been challenging to appropriately design these reirradiation treatments. It is therefore hugely rewarding to see our novel reirradiation tools and reirradiation research in Cancer Research UK RadNet Leeds reaching this important milestone. This will help realise the full potential of reirradiation for patients worldwide.”
New approach
Following the decade-long research into how reirradiation can be delivered more safely and effectively, the team has developed a suite of tools that clinicians can use when designing more targeted treatment for people who need reirradiation. The tools have now been introduced in the latest version of RaySearch’s treatment planning system, RayStation®, making them available to clinicians and scientists across the globe.
The tools allow clinicians to customise reirradiation by taking into account changes in patient anatomy and previous treatment. This helps determine the best radiotherapy dose to use to deliver safer and more effective reirradiation, with limited side effects.
Research impact
Professor Nick Plant, Pro-Vice-Chancellor: Research and Innovation, said: “At Leeds, our ambition is to turn research into improvements in health that benefit people in our region and around the world. This milestone demonstrates what can be achieved when university researchers, NHS healthcare professionals and industry work together to address the challenges faced by cancer patients.
“It is particularly rewarding to see a decade of research translated into clinical practice here in Leeds, with tools now available to support clinical teams across the globe. By sharing knowledge and translating discoveries into practical solutions, we can extend the impact of our research far beyond the place where it began, helping to improve patient care worldwide.”
Clinical collaboration
John Lilley, Head of External Beam Radiotherapy Physics at Leeds Teaching Hospitals NHS Trust, said: “Accounting for the previous radiotherapy when planning a new course is extremely challenging. Alongside our colleagues from the University of Leeds, we have been working for over ten years on the research that has underpinned the development of these new tools, and I am delighted that they are now available to teams in other hospitals. The tools will also give future radiotherapy trials better information about how changing the way that reirradiation is delivered influences the patients’ outcomes.”
Johan Löf, founder and CEO of RaySearch Laboratories, added: “One of RaySearch’s key strengths is the way we bring together scientific innovation and close collaboration with clinicians to develop advanced software that addresses real clinical needs. This milestone in reirradiation reflects our broader commitment to advancing cancer care and addressing complex treatment needs worldwide.”
Leeds Teaching Hospitals treats 7,800 patients with radiotherapy every year and has an international reputation for research excellence in this field.
Further information
Media enquiries can be emailed to University of Leeds press officer Lauren Ballinger via [email protected].
https://www.leeds.ac.uk/news/article/6056/cancer-treatment-world-first-in-leeds